Promise and challenges of anticoagulation with dabigatran

CKJ: Clinical Kidney Journal

Volumn 5, Issue 4, 2012, Pages 336-338

  Verma, Ashish ^a   Chhibber, Vishesh ^a   Emhoff, Timothy ^a   Klinger, Dagmar ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

bleeding; dabigatran; dialysis

Indexed keywords

DABIGATRAN; DABIGATRAN ETEXILATE; LISINOPRIL; METFORMIN; METOPROLOL; PROTHROMBIN; SIMVASTATIN; THROMBOPLASTIN;

ACTIVATED PLASMA THROMBOPLASTIN TIME; ADULT; ANTICOAGULANT THERAPY; BLOOD FLOW; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CRANIECTOMY; DRUG EFFICACY; HEMODIALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MEDICAL HISTORY; NEUROIMAGING; NEUROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; REVIEW; SKULL FRACTURE; STROKE; THROMBOCYTE COUNT; THROMBOPLASTIN TIME;

EID: 84864446194     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfs068     Document Type: Review

References (22)

1. Treatment of atrial fibrillation. Treat Guidel Med Lett 2010; 8: 65
2. US Food and Drug Administration News & Events. http://www. fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241. htm (date last accessed, 18 June 2012)
3. Strangier J. Clinical pharmacokinetics and pharmacody-namics of the oral direct thrombin inhibitor dabigatran etex-ilate. Clin Pharmacokinet 2008; 47: 285
4. Connolly SJ, Ezekowitz MD, Yusuf S et al. N Engl J Med 2009; 361: 1139-1151
5. Ma TK, Yan BP, Lam YY. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. Pharmacol Ther 2011; 129: 185-194
6. Hrebickova L, Nawarskas JJ, Anderson Jr. Ximelagatran: a new oral anticoagulant. Heart Dis 2003; 5: 397-408 (Pubitemid 37521685)
7. Dubois EA, Cohen AF. Dabigatran etexilate. Br J Clin Pharmacol 2010; 70: 14
8. Department of Health and Human Services. Dabigatran. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/CardiovascularandRenal DrugsAdvisoryCommittee/UCM247244.pdf (date last accessed, 18 June 2012)
9. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366: 864-866
10. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2684-2686
11. Bleeding with Dabigatran. Med Lett Drugs Ther 2011; 53: 98
12. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med 2011; 365: 2039-2040
13. Stangier J, Rathgen K, Stahle H et al. The pharmacokinetics, pharmacodynamics, and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64: 292-303 (Pubitemid 47283865)
14. Perry D, Todd T. Section on ECT testing. www.practical-hemostasis.com (date last accessed, 18 June 2012)
15. Lange U, Nowak G, Bucha E. Ecarin chromogenic assay-a new method for quantitative determination of direct throm-bin inhibitors like hirudin. Pathophysiol Haemost Thromb 2003; 33: 184-191 (Pubitemid 39664136)
16. van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127
17. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573
18. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15 (Suppl 1): 9S-16S
19. Yank V, Tuohy CV, Logan AC et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011; 154: 529-540
20. Pradaxa-package insert. Ridgefield, CT: Boehringer Ingel-heim Pharmaceuticals, Inc., 2010
21. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikel-boom JW. Recombinant factor VIIa (rFVIIa) and hemodialy-sis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119: 2172-2174
22. Cano EA, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Phar-macother 2012; 10: 160-163